Andrew Moin joined the SAB Board of Directors in October 2023, bringing over 15 years of expertise across investment management and law, and is a passionate supporter of the type 1 diabetes community. Mr. Moin is currently a Partner and Analyst at Sessa Capital, a New York based investment advisor registered with the SEC. Sessa Capital makes, on behalf of its funds and accounts, concentrated investments in value-oriented equity and debt securities, based on in-depth fundamental research. Mr. Moin has been with Sessa since 2012, where he works on idea generation, research, and investment implementation.
Prior to his time at Sessa, Mr. Moin was in the Tax Group at Sullivan & Cromwell LLP, where he advised corporate and other clients on a variety of transactions, including mergers & acquisitions, spinoffs, financings, and restructurings. He has also been deeply involved in the Type 1 Diabetes community for over 20 years, including as a volunteer and member of the Young Leadership Committee of the New York City Chapter of the JDRF and an early supporter of multiple fundamental diabetes research and innovation projects.
Mr. Moin has a B.A. in Economics, with distinction, from Amherst College, a J.D., magna cum laude, from Harvard Law School, and is a member of the New York Bar.